Additionally, JP stimulated the release of short-chain fatty acids (SCFAs) in rats with CKD, along with modulating the levels of kidney EPO mRNA and kidney EPO protein through HIF-α signaling. This evidence concerns the gene EPO and chronic kidney disease.